Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › The German Fast Track Toward Reimbursement of Digital Health Applications (DiGA) : Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes

Publication

The German Fast Track Toward Reimbursement of Digital Health Applications (DiGA) : Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes

Schliess, Freimut; Affini Dicenzo, Tatiana; Gaus, Nandor; u. a. (2026): The German Fast Track Toward Reimbursement of Digital Health Applications (DiGA) : Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes, in: Bamberg: Otto-Friedrich-Universität, S. 470–476.

Details

Faculty/Chair
Faculty/Professorship
Author
Schliess, Freimut; Affini Dicenzo, Tatiana; Gaus, Nandor; Bourez, Jean-Marc; Stegbauer, Constance; Szecsenyi, Joachim; Jacobsen, Malte; Müller-Wieland, Dirk; Kulzer, Bernhard; Heinemann, Lutz
Publisher Information
Otto-Friedrich-Universität : Bamberg
Year of publication
2026
Source/Other editions
Journal of Diabetes Science and Technology, London: Sage Publishing, 2022, Jg. 18, Nr. 2, S. 470–476, ISSN: 1932-2968
Year of first publication
2022
Language
English
Licence
URN
Abstract

Background: Digital health applications (DiGA) supporting the management of diabetes are among the most commonly available digital health technologies. However, transparent quality assurance of DiGA and clinical proof of a positive healthcare effect is often missing, which creates skepticism of some stakeholders regarding the usage and reimbursement of these applications.

Methods: This article reviews the recently established fast-track integration of DiGA in the German reimbursement market, with emphasis on the current impact for manufacturers, healthcare providers, and people with diabetes. The German DiGA fast track is contextualised with corresponding initiatives in Europe.

Results: The option of a provisional prescription and reimbursement of DiGA while proving a positive healthcare effect in parallel may expedite the adoption of DiGA in Germany and beyond. However, hurdles for a permanent prescription and reimbursement of DiGA are high and only one of 12 that have achieved this status specifically addresses people with diabetes.

Conclusion: The DiGA fast track needs to be further enhanced to cope with remaining skepticism and contribute even more to a value-based diabetes care.

Keywords
clinical trials
digital health
evidence
Germany
reimbursement
value-based healthcare
DDC Classification
150 Psychology
RVK Classification
CU 3000
Peer Reviewed
yes
International Distribution
yes
Open Access Journal
yes
Type
Article
URI
Activation date
2026-02-20

Permalink: https://fis.uni-bamberg.de/handle/uniba/113073 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-15

Restricted read-only access: login, editing and submission are temporarily disabled.